Nexentis Technologies Inc.（NXTS）株価・財務・リサーチ

日中の時刻はETです。市場データは遅延する場合があります。

企業プロフィール

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

業界: Agricultural Inputs
セクター: Basic Materials
本社: IL
最高経営責任者（CEO）: David Palach
上場以来: 2026年2月26日
従業員: 8

市場での位置

日中レンジ

現在 $1.77

$1.70$1.88

52週レンジ

現在 $1.77

$1.43$58.80

始値: $1.88
前日終値: $1.80
出来高: 7202; 0.01× 平均
平均出来高: 132.23万; 1日平均出来高
時価総額: 10.02万 USD
ベータ: 1.86; 市場参照 1
50日平均: $3.2611; 平均以下（-45.72%）
200日平均: $8.2214; 平均以下（-78.47%）

財務

財務スナップショット

直近12か月

バリュエーションと利回り

PER (TTM): -0.07×
P/B（TTM）: 0.76×
P/S（TTM）: -1.52×
配当利回り: 0.00%

収益性と効率性

粗利益率: 268.18%
営業利益率: 17754.55%
純利益率: 24283.33%

財務の健全性

負債資本比率: 0.22×
アルトマン Z スコア: -5.31
ピオトロスキー F スコア: 2 9件中

決算実績と見通し

最新のEPS結果: -25.96

EPS：実績と予想

直近の発表実績

実績予想

予想は利用できません

売上高：実績と予想

直近の発表実績

実績予想

予想は利用できません

NXTS ニュース

globenewswire.com2026年7月28日

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE ® -driven discovery…

ソースを読む

globenewswire.com2026年7月7日

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery…

ソースを読む

globenewswire.com2026年6月29日

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to…

ソースを読む

globenewswire.com2026年6月22日

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

ソースを読む

globenewswire.com2026年6月17日

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to…

ソースを読む